$3.45 Billion is the total value of Perceptive Advisors's 116 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRNX | CRINETICS PHARMACEUTICALS IN | $104,505,000 | +5.3% | 5,321,032 | 0.0% | 3.03% | -2.4% | |
| XENE | XENON PHARMACEUTICALS INC | $76,624,000 | +18.7% | 2,122,535 | 0.0% | 2.22% | +10.0% | |
| MGTX | MEIRAGTX HLDGS PLC | $58,561,000 | +11.1% | 6,963,277 | 0.0% | 1.70% | +3.0% | |
| TRAVERE THERAPEUTICS INCnote 2.250% 3/0 | $45,980,000 | -89.9% | 45,000,000 | 0.0% | 1.33% | -90.7% | ||
| LYRA | LYRA THERAPEUTICS INC | $45,825,000 | -11.3% | 9,146,730 | 0.0% | 1.33% | -17.9% | |
| ALBO | ALBIREO PHARMA INC | $45,692,000 | -2.5% | 2,360,139 | 0.0% | 1.33% | -9.7% | |
| RLAY | RELAY THERAPEUTICS INC | $43,467,000 | +33.6% | 1,943,097 | 0.0% | 1.26% | +23.7% | |
| VBIV | VBI VACCINES INC CDA | $37,157,000 | -12.2% | 52,335,002 | 0.0% | 1.08% | -18.6% | |
| NUVALENT INC | $32,173,000 | +43.4% | 1,655,007 | 0.0% | 0.93% | +32.9% | ||
| IMTX | IMMATICS N.V | $25,000,000 | +14.8% | 2,500,000 | 0.0% | 0.73% | +6.5% | |
| TARS | TARSUS PHARMACEUTICALS INC | $22,194,000 | +17.3% | 1,296,416 | 0.0% | 0.64% | +8.6% | |
| NAUT | NAUTILUS BIOTECHNOLOGY INC | $19,315,000 | -21.2% | 9,111,151 | 0.0% | 0.56% | -27.0% | |
| HRMY | HARMONY BIOSCIENCES HLDGS IN | $18,239,000 | -9.2% | 411,804 | 0.0% | 0.53% | -15.9% | |
| BBIO | BRIDGEBIO PHARMA INC | $16,869,000 | +9.5% | 1,697,033 | 0.0% | 0.49% | +1.4% | |
| VRCA | VERRICA PHARMACEUTICALS INC | $14,714,000 | +52.1% | 5,038,983 | 0.0% | 0.43% | +40.9% | |
| CNCE | CONCERT PHARMACEUTICALS INC | $14,409,000 | +59.1% | 2,150,641 | 0.0% | 0.42% | +47.2% | |
| ATHA | ATHIRA PHARMA INC | $14,248,000 | -2.6% | 4,797,278 | 0.0% | 0.41% | -9.6% | |
| HILLEVAX INC | $13,072,000 | +56.4% | 764,907 | 0.0% | 0.38% | +44.7% | ||
| RAIN | RAIN THERAPEUTICS INC | $12,120,000 | -12.2% | 2,483,619 | 0.0% | 0.35% | -18.7% | |
| ASTRIA THERAPEUTICS INC | $11,582,000 | +201.4% | 1,281,197 | 0.0% | 0.34% | +180.0% | ||
| MORF | MORPHIC HLDG INC | $10,278,000 | +30.4% | 363,197 | 0.0% | 0.30% | +20.6% | |
| LABP | LANDOS BIOPHARMA INC | $9,665,000 | -10.7% | 14,869,915 | 0.0% | 0.28% | -17.4% | |
| OMIC | SINGULAR GENOMICS SYSTEMS IN | $8,841,000 | -34.6% | 3,536,274 | 0.0% | 0.26% | -39.2% | |
| ISOPLEXIS CORP | $7,044,000 | -20.4% | 4,095,498 | 0.0% | 0.20% | -26.4% | ||
| CCCC | C4 THERAPEUTICS INC | $6,720,000 | +16.3% | 766,231 | 0.0% | 0.20% | +7.7% | |
| SLDB | SOLID BIOSCIENCES INC | $6,258,000 | -24.2% | 13,412,552 | 0.0% | 0.18% | -29.7% | |
| ACRS | ACLARIS THERAPEUTICS INC | $5,371,000 | +12.7% | 341,239 | 0.0% | 0.16% | +4.7% | |
| ENVVENO MEDICAL CORPORATION | $4,909,000 | +66.2% | 781,615 | 0.0% | 0.14% | +52.7% | ||
| SEMA4 HOLDINGS CORP | $4,390,000 | -30.3% | 5,000,000 | 0.0% | 0.13% | -35.5% | ||
| SOMALOGIC INC | $4,350,000 | -35.8% | 1,500,000 | 0.0% | 0.13% | -40.6% | ||
| TYRA BIOSCIENCES INC | $4,346,000 | +22.9% | 494,403 | 0.0% | 0.13% | +13.5% | ||
| NBTX | NANOBIOTIXsponsored ads | $3,752,000 | -6.8% | 1,059,800 | 0.0% | 0.11% | -13.5% | |
| COHERUS BIOSCIENCES INCnote 1.500% 4/1 | $3,592,000 | -87.8% | 4,500,000 | 0.0% | 0.10% | -88.7% | ||
| YMAB | Y-MABS THERAPEUTICS INC | $3,057,000 | -4.7% | 212,018 | 0.0% | 0.09% | -11.0% | |
| PYXIS ONCOLOGY INC | $3,012,000 | -17.2% | 1,528,812 | 0.0% | 0.09% | -23.7% | ||
| ABSCI CORPORATION | $2,799,000 | -5.7% | 894,346 | 0.0% | 0.08% | -12.9% | ||
| CLOV | CLOVER HEALTH INVESTMENTS CO | $2,550,000 | -20.6% | 1,500,000 | 0.0% | 0.07% | -26.7% | |
| QTNT | QUOTIENT LTD | $2,430,000 | -37.5% | 16,200,818 | 0.0% | 0.07% | -41.8% | |
| SCIENCE 37 HOLDINGS INC | $2,415,000 | -19.9% | 1,500,000 | 0.0% | 0.07% | -25.5% | ||
| FULC | FULCRUM THERAPEUTICS INC | $2,379,000 | +65.1% | 294,118 | 0.0% | 0.07% | +53.3% | |
| PEAR THERAPEUTICS INC | $1,837,000 | +32.5% | 900,548 | 0.0% | 0.05% | +23.3% | ||
| DARIOHEALTH CORP | $1,518,000 | -24.6% | 327,869 | 0.0% | 0.04% | -30.2% | ||
| TARA | PROTARA THERAPEUTICS INC | $859,000 | +1.1% | 290,051 | 0.0% | 0.02% | -7.4% | |
| PRVB | PROVENTION BIO INC | $498,000 | +12.4% | 110,728 | 0.0% | 0.01% | 0.0% | |
| EQRX INC*w exp 12/17/202 | $205,000 | +1.0% | 250,000 | 0.0% | 0.01% | 0.0% | ||
| AGILE THERAPEUTICS INC | $158,000 | -74.5% | 532,361 | 0.0% | 0.01% | -73.7% | ||
| CMAXW | CAREMAX INC*w exp 06/08/202 | $113,000 | +162.8% | 60,000 | 0.0% | 0.00% | +200.0% | |
| NEPTUNE WELLNESS SOLUTIONS I | $87,000 | +7.4% | 57,142 | 0.0% | 0.00% | 0.0% | ||
| SURROZEN INC*w exp 08/01/203 | $31,000 | -3.1% | 166,666 | 0.0% | 0.00% | 0.0% | ||
| SURROZEN INC | $12,000 | -33.3% | 6,017 | 0.0% | 0.00% | -100.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
About Perceptive Advisors
Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.
The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.
One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.
Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES SHARES | 42 | Q3 2023 | 15.7% |
| AMICUS THERAPEUTICS SHARES | 39 | Q3 2023 | 14.0% |
| ALDEYRA THERAPEUTICS SHARES | 35 | Q3 2023 | 3.3% |
| QUOTIENT TECHNOLOGY INC | 34 | Q3 2022 | 2.7% |
| GLOBAL BLOOD THERAPEUTICS SHARES | 29 | Q3 2022 | 9.3% |
| ADMA BIOLOGICS SHARES | 29 | Q3 2023 | 1.4% |
| RETROPHIN SHARES | 28 | Q3 2020 | 5.5% |
| DBV TECHNOLOGIES SA-SPON ADR | 28 | Q3 2021 | 1.8% |
| VBI VACCINES SHARES | 27 | Q1 2023 | 2.8% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
View Perceptive Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHEMBIO DIAGNOSTICS, INC.Sold out | May 04, 2023 | 0 | 0.0% |
| VBI Vaccines Inc/BC | April 07, 2023 | 43,509,553 | 16.7% |
| Landos Biopharma, Inc. | March 30, 2023 | 14,869,915 | 47.7% |
| REATA PHARMACEUTICALS INC | March 07, 2023 | 2,083,799 | 6.5% |
| AGILE THERAPEUTICS INCSold out | February 14, 2023 | 0 | 0.0% |
| ALBIREO PHARMA, INC. | February 14, 2023 | 1,757,160 | 8.5% |
| BELLUS Health Inc. | February 14, 2023 | 8,891,027 | 7.1% |
| CinCor Pharma, Inc. | February 14, 2023 | 2,576,325 | 5.9% |
| Coherus BioSciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CONCERT PHARMACEUTICALS, INC. | February 14, 2023 | 1,800,000 | 3.6% |
View Perceptive Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-15 |
| SC 13G/A | 2024-04-15 |
| SC 13G | 2024-04-15 |
| SC 13D/A | 2024-04-10 |
| 4 | 2024-04-08 |
| 4 | 2024-04-03 |
| SC 13D/A | 2024-04-03 |
| SC 13D | 2024-03-20 |
| SC 13G | 2024-03-14 |
| SC 13G | 2024-03-11 |
View Perceptive Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.